<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360e–3" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360e–3/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360e–3/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360e_3"><akn:num>360e–3</akn:num><akn:heading>Breakthrough devices</akn:heading><akn:content><akn:p>§ 360e–3. Breakthrough devices(a) PurposeThe purpose of this section is to encourage the Secretary, and provide the Secretary with sufficient authority, to apply efficient and flexible approaches to expedite the development of, and prioritize the Food and Drug Administration’s review of, devices that represent breakthrough technologies.


(b) Establishment of programThe Secretary shall establish a program to expedite the development of, and provide for the priority review for, devices, as determined by the Secretary—(1) that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions; and

(2)(A) that represent breakthrough technologies;

(B) for which no approved or cleared alternatives exist;

(C) that offer significant advantages over existing approved or cleared alternatives, including the potential, compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients’ ability to manage their own care (such as through self-directed personal assistance), or establish long-term clinical efficiencies; or

(D) the availability of which is in the best interest of patients.



(c) Request for designationA sponsor of a device may request that the Secretary designate such device for expedited development and priority review under this section. Any such request for designation may be made at any time prior to the submission of an application under section 360e(c) of this title, a notification under section 360(k) of this title, or a petition for classification under section 360c(f)(2) of this title.


(d) Designation process(1) In generalNot later than 60 calendar days after the receipt of a request under subsection (c), the Secretary shall determine whether the device that is the subject of the request meets the criteria described in subsection (b). If the Secretary determines that the device meets the criteria, the Secretar</akn:p></akn:content><akn:subsection eId="subsec_360e_3_a"><akn:num>(a)</akn:num><akn:heading>Purpose</akn:heading><akn:content><akn:p>(a) Purpose The purpose of this section is to encourage the Secretary, and provide the Secretary with sufficient authority, to apply efficient and flexible approaches to expedite the development of, and prioritize the Food and Drug Administration’s review of, devices that represent breakthrough technologies.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360e_3_b"><akn:num>(b)</akn:num><akn:heading>Establishment of program</akn:heading><akn:content><akn:p>(b) Establishment of program The Secretary shall establish a program to expedite the development of, and provide for the priority review for, devices, as determined by the Secretary—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360e_3_c"><akn:num>(c)</akn:num><akn:heading>Request for designation</akn:heading><akn:content><akn:p>(c) Request for designation A sponsor of a device may request that the Secretary designate such device for expedited development and priority review under this section. Any such request for designation may be made at any time prior to the submission of an application under section 360e(c) of this title, a notification under section 360(k) of this title, or a petition for classification under section 360c(f)(2) of this title.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360e_3_d"><akn:num>(d)</akn:num><akn:heading>Designation process</akn:heading><akn:content><akn:p>(d) Designation process</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360e_3_e"><akn:num>(e)</akn:num><akn:heading>Expedited development and priority review</akn:heading><akn:content><akn:p>(e) Expedited development and priority review</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360e_3_f"><akn:num>(f)</akn:num><akn:heading>Priority review guidance</akn:heading><akn:content><akn:p>(f) Priority review guidance</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360e_3_g"><akn:num>(g)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(g) Rule of construction Nothing in this section shall be construed to affect—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>